Glucose predictor

An EU consortium is currently reviewing initial results from a clinical trial of diabetic patients who used a new blood glucose predictor technology.

The technology, which was developed through the EU-funded DIAdvisor project, encompasses hardware, software and sensors from Toumaz Technology, based in Abingdon.

DIAdvisor aims to develop a prediction-based tool that uses past and easily available information to optimise the therapy of type I and type II diabetes.

The technology will allow patients to actively and accurately predict their short-term blood glucose outlook at any time by analysing data retrieved from glucose measurements, insulin delivery data and specific patient parameters.

The key data, captured by non-intrusive body-worn wireless monitors including those based on Toumaz’s Sensium technology, will be used to create physiological mathematical modelling, control and prediction algorithms.

The resulting analysis and prediction information will be wirelessly transmitted to a healthcare provider advisory service, with recommended action and treatment advice presented to the patient through a hand-held mobile device such as a personal digital assistant (PDA).